MEM ANT 3310
Alternative Names: MEM-ANT3310; Meropenem + ANT-3310; SBLi-AntabioLatest Information Update: 24 Aug 2026
At a glance
- Originator Antabio
- Class Anti-infectives; Antibacterials; Small molecules; Urinary anti-infective agents
- Mechanism of Action Beta Lactamase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Infections; Intra-abdominal infections; Kidney disorders; Nosocomial infections; Urinary tract infections
Most Recent Events
- 30 Jul 2026 Antabio terminates a phase I pharmacokinetics trial in Healthy volunteers in France (IV) (CTIS2026-526411-11-00)
- 29 Jun 2026 Phase-I development is ongoing in France (IV) (Antabio website, June 2026)
- 17 Jun 2026 Antabio initiates a phase I pharmacokinetics trial in Healthy volunteers in France (IV) (CTIS2026-526411-11-00)